62 related articles for article (PubMed ID: 17187699)
1. Presentation of a functional pituitary adenoma as a significant decrease in prostate-specific antigen level in a patient followed for prostate cancer.
Grotas AB; Nagler HM
Can J Urol; 2006 Dec; 13(6):3346-7. PubMed ID: 17187699
[TBL] [Abstract][Full Text] [Related]
2. Chronic anemia as first clinical manifestation of a prolactin-secreting pituitary macroadenoma in a male patient.
Iglesias P; Díez JJ
Am J Med; 2011 Jun; 124(6):e3-4. PubMed ID: 21605718
[No Abstract] [Full Text] [Related]
3. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
[TBL] [Abstract][Full Text] [Related]
4. Dramatic shrinkage of a giant prolactinoma in a male patient under medical management.
Ippersiel W; Misson N; Donckier JE
Acta Clin Belg; 2012; 67(2):140-1. PubMed ID: 22712173
[No Abstract] [Full Text] [Related]
5. Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline.
Dash S; Annamalai AK; Simpson HL; Sarkies N; Antoun NM; Mannion R
QJM; 2013 Jan; 106(1):85. PubMed ID: 22075008
[No Abstract] [Full Text] [Related]
6. [Pharmacologic cure of a pituitary macroprolactinoma].
Hurtado Amador R; Ayala AR
Ginecol Obstet Mex; 2003 Oct; 71():522-6. PubMed ID: 15002692
[TBL] [Abstract][Full Text] [Related]
7. [Capacities of chemotherapy for pituitary tumors].
Vaks VV; Dedov II
Zh Vopr Neirokhir Im N N Burdenko; 2005; (2):30-6; discussion 36-7. PubMed ID: 16078633
[No Abstract] [Full Text] [Related]
8. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
9. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
11. Misdiagnosis due to the hook effect in prolactin assay.
Yener S; Comlekci A; Arda N; Men S; Yesil S
Med Princ Pract; 2008; 17(5):429-31. PubMed ID: 18685288
[TBL] [Abstract][Full Text] [Related]
12. Pituitary apoplexy within a macroprolactinoma.
Watt A; Pobereskin L; Vaidya B
Nat Clin Pract Endocrinol Metab; 2008 Nov; 4(11):635-41. PubMed ID: 18797434
[TBL] [Abstract][Full Text] [Related]
13. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
Werner S
Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
[No Abstract] [Full Text] [Related]
14. Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2011 Nov; 31(11):3913-20. PubMed ID: 22110219
[TBL] [Abstract][Full Text] [Related]
15. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
16. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
17. Impact of neoadjuvant prostate-specific antigen kinetics on biochemical failure and prostate cancer mortality: results from a prospective patient database.
Foo M; Lavieri M; Pickles T
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):385-92. PubMed ID: 22652112
[TBL] [Abstract][Full Text] [Related]
18. Soy isoflavones in the treatment of prostate cancer.
Hussain M; Banerjee M; Sarkar FH; Djuric Z; Pollak MN; Doerge D; Fontana J; Chinni S; Davis J; Forman J; Wood DP; Kucuk O
Nutr Cancer; 2003; 47(2):111-7. PubMed ID: 15087261
[TBL] [Abstract][Full Text] [Related]
19. Advanced prostate cancer with extremely low prostate-specific antigen value at diagnosis: an example of high dose hook effect.
Akamatsu S; Tsukazaki H; Inoue K; Nishio Y
Int J Urol; 2006 Jul; 13(7):1025-7. PubMed ID: 16882082
[TBL] [Abstract][Full Text] [Related]
20. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Herrada J; Dieringer P; Logothetis CJ
J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
